Pharma
Trevia (Sitagliptin Tablets USP 100 mg)
DPP-4 inhibitor; 100 mg Sitagliptin tablets for the management of Type 2 Diabetes.
Trevia (Sitagliptin Tablets USP 100 mg)
Trevia 100 mg contains Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor designed to improve blood sugar control in adults with type 2 diabetes mellitus. It functions by protecting incretin hormones from degradation, which in turn signals the pancreas to produce more insulin and the liver to produce less glucose. It is intended for use alongside diet and exercise to manage glycemic levels. This medication is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Side effects may include nasopharyngitis, upper respiratory tract infection, and headache.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.